Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells

mAbs

Volumn 5, Issue 1, 2013, Pages 34-46

  Marcucci, Fabrizio ^a,b   Bellone, Matteo ^c   Rumio, Cristiano ^d   Corti, Angelo ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Hepatology Association of Calabria   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Accumulation; ADCC; Affinity; Cancer; Immune cells; Mechanism of action; Monoclonal antibodies; Therapy

Indexed keywords

BEVACIZUMAB; CELL SURFACE RECEPTOR; CETUXIMAB; CONATUMUMAB; DROZITUMAB; IPILIMUMAB; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PANITUMUMAB; RITUXIMAB; TAS 266; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NONHUMAN; PROTEIN BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MICE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84872867897     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22775     Document Type: Article

References (131)

1. Reichert JM, Rosensweig CJ, Faden L.B., Dewitz MC Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-8; PMID:16151394; http://dx.doi.org/10.1038/nbt0905-1073
2. Scott AM, Wolchok JD, Old LJ Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
4. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 15:7479-91; PMID:20008848; http://dx.doi.org/10. 1158/1078-0432.CCR-09-0636
5. Clynes RA, Towers TL, Presta L.G., Ravetch JV Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
6. Glennie MJ, van de Winkel JGJ. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003; 8:503-10; PMID:12818520; http://dx.doi.org/10.1016/S1359-6446(03)02714-4
7. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007; 39:271-8; PMID:17917071; http://dx.doi.org/10.1007/s12026-007-0073-4
8. Chan HTC, Hughes D, French R.R., Tutt AL, Walshe CA, Teeling JL, et al CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003; 63:5480-9; PMID:14500384
9. Ivanov A, Beers SA, Walshe C.A., Honeychurch J., Alduaij W, Cox KL, et al Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143-59; PMID:19620786
10. Honeychurch J, Alduaij W, Azizyan M., Cheadle EJ, Pelicano H, Ivanov A, et al Antibody-induced non-apoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119:3523-33; PMID:22354003; http://dx.doi.org/10.1182/blood-2011-12- 395541
11. Lim SH, Beers SA, French R.R., Johnson PWM, Glennie MJ, Cragg MS Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135-43; PMID:19773256; http://dx.doi.org/10.3324/ haematol.2008.001628
12. Alduaij W, Illidge TM The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 2011; 117:2993-3001; PMID:21209380; http://dx.doi.org/10.1182/blood-2010-07-298356
13. Link BK, Martin P, Kaminski M.S., Goldsmith SJ, Coleman M, Leonard J P. Cyclophosphamide, vincris-tine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010; 28:3035-41; PMID:20458031; http://dx.doi.org/10.1200/JCO.2009.27.8325
14. Mössner E., Brünker P, Moser S., Püntener U, Schmidt C., Herter S, et al Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979
15. Salles G, Morschhauser F, Lamy T., Milpied N, Thieblemont C, Tilly H., et al Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119:5126-32; PMID:22431570; http://dx.doi.org/10.1182/blood-2012-01-404368
16. Buchsbaum DJ, Forero-Torres A, LoBuglio A F. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol 2007; 3:405-9; PMID:17661715; http://dx.doi.org/10.2217/14796694.3.4.405
17. Wilson NS, Yang B, Yang A., Loeser S, Marsters S, Lawrence D., et al An FCγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19:101-13; PMID:21251615; http://dx.doi.org/10.1016/j.ccr.2010.11.012
18. Trarbach T, Moehler M, Heinemann V., Köhne CH, Przyborek M., Schulz C, et al Phase II trial of mapatu-mumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102:506-12; PMID:20068564; http://dx.doi.org/10.1038/sj.bjc.6605507
19. Plummer R, Attard G, Pacey S., Li L, Razak A, Perrett R., et al Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13:6187-94; PMID:17947486; http://dx.doi.org/10.1158/1078- 0432.CCR-07-0950
20. Wakelee HA, Patnaik A, Sikic B.I., Mita M., Fox NL, Miceli R, et al Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21:376-81; PMID:19633048; http://dx.doi.org/10.1093/annonc/mdp292
21. Camidge DR, Herbst RS, Gordon M.S., Eckhardt SG, Kurzrock R, Durbin B, et al A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16:1256-63; PMID:20145186; http://dx.doi.org/10.1158/1078-0432.CCR-09-1267
22. Herbst RS, Kurzrock R, Hong D.S., Valdivieso M., Hsu C P, Goyal L, et al A first-in-human study of conatu-mumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16:5883-91; PMID:20947515; http://dx.doi.org/10. 1158/1078-0432.CCR-10-0631
23. Huet H, Schuller A, Li J., Johnson J, Dombrecht B, Meerschaert K., et al TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches. Philadelphia (PA): AACR; Cancer Res 2012; 72(8 Suppl):Abstract nr 3853. doi:1538-7445.AM2012-3853
24. Hurwitz H, Fehrenbacher L, Novotny W., Cartwright T, Hainsworth J, Heim W., et al Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691
25. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn L.L., Tong RT, et al Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7; PMID:14745444; http://dx.doi.org/10.1038/nm988
26. Marcucci F, Corti A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012; 64:53-68; PMID:21983328; http://dx.doi.org/10.1016/j.addr.2011. 09.007
27. Yang JC, Haworth L, Sherry R.M., Hwu P., Schwartzentruber DJ, Topalian SL, et al A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34; PMID:12890841; http://dx.doi.org/10.1056/NEJMoa021491
28. Fischer C, Jonckx B, Mazzone M., Zacchigna S, Loges S, Pattarini L., et al Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131:463-75; PMID:17981115; http://dx.doi.org/10.1016/j.cell.2007.08.038
29. Herbst RS, Hong D, Chap L., Kurzrock R, Jackson E, Silverman J.M., et al Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27:3557-65; PMID:19546406; http://dx.doi.org/10.1200/JCO.2008.19. 6683
30. Huang H, Lai J-Y, Do J, Liu D., Li L, Del Rosario J, et al Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17:1001-11; PMID:21233403; http://dx.doi.org/10.1158/1078-0432.CCR-10-2317
31. Rosen PJ, Sweeney CJ, Park D.J., Beaupre DM, Deng H, Leitch IM, et al A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2677-87; PMID:20406832; http://dx.doi.org/10.1158/1078-0432.CCR-09-2862
32. Bagatell R, Herzog CE, Trippett T.M., Grippo J F, Cirrincione-Dall G, Fox E., et al Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011; 17:611-9; PMID:21127194; http://dx.doi.org/10.1158/1078-0432. CCR-10-1731
33. Huang J, Ni J, Liu K., Yu Y, Xie M, Kang R., et al HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 2012; 72:230-8; PMID:22102692; http://dx.doi.org/10.1158/0008-5472.CAN-11-2001
34. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/ NEJMra043186
35. Karapetis CS, Khambata-Ford S, Jonker D.J., O'Callaghan CJ, Tu D, Tebbutt N.C., et al K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10. 1056/NEJMoa0804385
36. Amado RG, Wolf M, Peeters M., Van Cutsem E, Siena S, Freeman D.J., et al Wild-type KRAS is required for panitumumab efficacy in patients with meta-static colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
37. Roberts PJ, Stinchcombe TE, Der C.J., Socinski MA Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28:4769-77; PMID:20921461; http://dx.doi.org/10.1200/JCO.2009.27.4365
38. Varchetta S, Gibelli N, Oliviero B., Nardini E, Gennari R, Gatti G., et al Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67:11991-9; PMID:18089830; http://dx.doi.org/10.1158/0008-5472.CAN-07-2068
39. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M., Blanchard F, et al Impact of FCγRIIa-FCγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-9; PMID:19164213; http://dx.doi.org/10.1200/JCO.2008.18.0463
40. Elter T, Borchmann P, Schulz H., Reiser M, Trelle S, Schnell R., et al Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23:7024-31; PMID:16145065; http://dx.doi.org/10.1200/JCO.2005.01.9950
41. Golay J, Manganini M, Rambaldi A., Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89:1476-83; PMID:15590398
42. Zent CS, Secreto CR, LaPlant B.R., Bone ND, Call TG, Shanafelt TD, et al Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008; 32:1849-56; PMID:18584865; http://dx.doi.org/10.1016/j.leukres.2008.05.014
43. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010; 28:3525-30; PMID:20458041; http://dx.doi.org/10.1200/JCO.2010.27.9836
44. Lemery SJ, Zhang J, Rothmann M.D., Yang J., Earp J, Zhao H, et al U.S. Clin Cancer Res 2010; 16:4331-8; PMID:20601446; http://dx.doi.org/10.1158/1078- 0432.CCR-10-0570
45. Tawara T, Hasegawa K, Sugiura Y., Harada K, Miura T, Hayashi S., et al Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol 2008; 180:2294-8; PMID:18250438
46. van der Kolk LE, Grillo-López AJ, Baars J W, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807-11; PMID:11843813; http://dx.doi.org/10. 1046/j.1365-2141.2001.03166.x
47. Wang SY, Racila E, Taylor R P, Weiner GJ NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008; 111:1456-63; PMID:18024795; http://dx.doi.org/10.1182/blood-2007-02-074716
48. Rutkowski MJ, Sughrue ME, Kane A.J., Mills SA, Parsa AT Cancer and the complement cascade. Mol Cancer Res 2010; 8:1453-65; PMID:20870736; http://dx.doi.org/10.1158/1541-7786.MCR-10-0225
49. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, et al Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
50. Robert C, Thomas L, Bondarenko I., O'Day S, Md JW, Garbe C, et al Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
51. Vonderheide RH, LoRusso PM, Khalil M, Gartner E.M., Khaira D., Soulieres D, et al Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010; 16:3485-94; PMID:20479064; http://dx.doi.org/10.1158/1078-0432.CCR-10-0505
52. Brahmer JR, Drake CG, Wollner I, Powderly J.D., Picus J., Sharfman WH, et al Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacody-namics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
53. Hilchey S.P., Hyrien O, Mosmann T.R., Livingstone AM, Friedberg JW, Young F, et al Rituximab immunotherapy results in the induction of a lymphoma idio-type-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009; 113:3809-12; PMID:19196657; http://dx.doi.org/10.1182/blood-2008-10-185280
54. rd, Scullin DC Jr., Corso S W, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-7; PMID:12377971; http://dx.doi.org/10.1200/JCO.2002.08.674
55. Abès R., Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926-34; PMID:20439625; http://dx.doi.org/10.1182/ blood-2009-10-248609
56. Selenko N, Maidic O, Draxier S., Berer A, Jäger U, Knapp W., et al CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15:1619-26; PMID:11587221; http://dx.doi.org/10.1038/sj.leu.2402226
57. Park SG, Jiang Z, Mortenson E.D., Deng L., Radkevich-Brown O, Yang X, et al The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70; PMID:20708157; http://dx.doi.org/10.1016/j.ccr.2010.06.014
58. zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastu-zumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002; 62:2244-7; PMID:11956077
59. Arnould L, Gelly M, Penault-Llorca F, Benoit L., Bonnetain F, Migeon C, et al Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94:259-67; PMID:16404427; http://dx.doi.org/10.1038/sj.bjc.6602930
60. Taylor C, Hershman D, Shah N., Suciu-Foca N, Petrylak D P, Taub R, et al Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13:5133-43; PMID:17785568; http://dx.doi.org/10.1158/1078-0432.CCR-07-0507
61. Zhou Z, Bolontrade MF, Reddy K, Duan X., Guan H, Yu L, et al Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007; 13:4867-73; PMID:17699866; http://dx.doi.org/10.1158/1078-0432. CCR-07-0133
62. Loeffler M, Krüger JA, Niethammer A.G., Reisfeld RA Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116:1955-62; PMID:16794736; http://dx.doi.org/10.1172/JCI26532
63. Schmidt MM, Wittrup KD A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8:2861-71; PMID:19825804; http://dx.doi.org/10.1158/1535-7163.MCT-09-0195
64. Bargou R, Leo E, Zugmaier G., Klinger M, Goebeler M, Knop S., et al Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/science. 1158545
65. O'Dwyer P.J., Manola J, Valone F.H., Ryan LM, Hines JD, Wadler S, et al Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-I-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule-an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 2001; 19:2413-21; PMID:11331320
66. Ning S, Tian J, Marshall D.J., Knox SJ Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res 2010; 70:7591-9; PMID:20841470; http://dx.doi.org/10.1158/0008-5472.CAN-10-1639
67. Thurber GM, Schmidt MM, Wittrup KD Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008; 60:1421-34; PMID:18541331; http://dx.doi.org/10.1016/j.addr.2008.04.012
68. Mantovani A, Allavena P, Sica A., Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/ nature07205
69. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301-14; PMID:7507411; http://dx.doi.org/10.1016/0092-8674(94)90337-9
70. Piali L, Fichtel A, Terpe H-J, Imhof BA, Gisler RH Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181:811-6; PMID:7530765; http://dx.doi.org/10.1084/jem.181.2.811
71. Wu NZ, Klitzman B, Dodge R., Dewhirst MW Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992; 52:4265-8; PMID:1638539
72. Nooijen PTGA, Westphal JR, Eggermont AMM, Schalkwijk C, Max R., de Waal RMW, et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 1998; 152:679-82; PMID:9502409
73. Zhang H, Issekutz AC Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am J Pathol 2002; 160:2219-30; PMID:12057924; http://dx.doi.org/10.1016/S0002-9440(10)61169-8
74. Pagès F., Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/onc.2009.416
75. Gennari R, Menard S, Fagnoni F., Ponchio L, Scelsi M, Tagliabue E., et al Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:5650-5; PMID:15355889; http://dx.doi.org/10.1158/1078-0432.CCR-04-0225
76. Cartron G, Dacheux L, Salles G., Solal-Celigny P, Bardos P, Colombat P., et al Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
77. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10. 1200/JCO.2003.05.013
78. Treon S.P., Hansen M, Branagan A.R., Verselis S., Emmanouilides C, Kimby E, et al Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005; 23:474-81; PMID:15659493; http://dx.doi.org/10.1200/JCO.2005. 06.059
79. Musolino A, Naldi N, Bortesi B., Pezzuolo D, Capelletti M, Missale G., et al Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10. 1200/JCO.2007.14.8957
80. Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011; 17:5668-73; PMID:21788356; http://dx.doi.org/10.1158/1078-0432.CCR-11-0239
81. Tol J, Koopman M, Cats A., Rodenburg CJ, Creemers GJ, Schrama JG, et al Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-72; PMID:19196673; http://dx.doi.org/10.1056/NEJMoa0808268
82. Bonertz A, Weitz J, Pietsch D-HK, Rahbari NN, Schlude C, Ge Y., et al Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21; PMID:19809157
83. Liotta F, Gacci M, Frosali F., Querci V, Vittori G, Lapini A., et al Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2011; 107:1500-6; PMID:20735382; http://dx.doi.org/10.1111/j.1464-410X.2010. 09555.x
84. Netti PA, Hamberg LM, Babich J W, Kierstead D, Graham W., Hunter GJ, et al Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999; 96:3137-42; PMID:10077650; http://dx.doi.org/10.1073/pnas.96.6.3137
85. Nakahara T, Norberg SM, Shalinsky D.R., Hu-Lowe DD, McDonald DM Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006; 66:1434-45; PMID:16452199; http://dx.doi.org/10.1158/0008-5472.CAN-05-0923
86. Khawli LA, Hu P, Epstein AL NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res 2005; 11:3084-93; PMID:15837764; http://dx.doi.org/10.1158/1078-0432.CCR-04-2310
87. Khawli LA, Miller GK, Epstein AL Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994; 73(Suppl):824-31; PMID:8306266; http://dx.doi.org/10.1002/1097- 0142(19940201)73:3+<824::AID-CNCR2820731312>3.0.CO;2-V
88. Sugahara KN, Teesalu T, Karmali P P, Kotamraju VR, Agemy L, Girard O.M., et al Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009; 16:510-20; PMID:19962669; http://dx.doi.org/10.1016/j.ccr. 2009.10.013
89. Sugahara KN, Teesalu T, Karmali P P, Kotamraju VR, Agemy L, Greenwald D.R., et al Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010; 328:1031-5; PMID:20378772; http://dx.doi.org/10.1126/sci-ence.1183057
90. Beyer I, van Rensburg R, Strauss R, Li Z.Y., Wang H., Persson J, et al Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011; 71:7080-90; PMID:21990319; http://dx.doi.org/10.1158/0008-5472. CAN-11-2009
91. Beyer I, Li Z, Persson J., Liu Y, van Rensburg R, Yumul R, et al Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 2011; 19:479-89; PMID:21081901; http://dx.doi.org/10.1038/mt.2010.256
92. Choi IK, Lee YS, Yoo J.Y., Yoon AR, Kim H, Kim DS, et al Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010; 17:190-201; PMID:19907500; http://dx.doi.org/10. 1038/gt.2009.142
93. Pietras K, Östman A, Sjöquist M, Buchdunger E, Reed RK, Heldin C-H, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-34; PMID:11306470
94. Pietras K, Rubin K, Sjöblom T, Buchdunger E., Sjöquist M, Heldin C-H, et al Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62:5476-84; PMID:12359756
95. Pietras K, Stumm M, Hubert M., Buchdunger E, Rubin K, Heldin C-H, et al STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003; 9:3779-87; PMID:14506171
96. Baranowska-Kortylewicz J., Abe M, Pietras K., Kortylewicz Z P, Kurizaki T, Nearman J., et al Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res 2005; 65:7824-31; PMID:16140951
97. Eikenes L, Bruland OS, Brekken C, Davies CdeL. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 2004; 64:4768-73; PMID:15256445; http://dx.doi.org/10.1158/0008-5472.CAN-03-1472
98. Brekken C, Hjelstuen MH, Bruland O.S., de Lange Davies C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res 2000; 20(5B):3513-9; PMID:11131655
99. rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006; 66:517-26; PMID:16397268; http://dx.doi.org/10.1158/0008-5472.CAN-05-2429
100. Repka T, Chiorean EG, Gay J, Herwig K.E., Kohl VK, Yee D, et al Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003; 9:2440-6; PMID:12855616
101. rd, Caligiuri M, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 2002; 8:3718-27; PMID:12473581
102. Gluck WL, Hurst D, Yuen A., Levine AM, Dayton MA, Gockerman J P, et al Phase I studies of inter-leukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253-64; PMID:15073100; http://dx.doi.org/ 10.1158/1078-0432.CCR-1087-3
103. Cheung IY, Hsu K, Cheung N-KV. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012; 30:426-32; PMID:22203761; http://dx.doi.org/10.1200/ JCO.2011.37.6236
104. Yu AL, Gilman AL, Ozkaynak M.F., London WB, Kreissman SG, Chen HX, et al; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
105. Hernandez-Ilizaliturri F.J., Reddy N, Holkova B., Ottman E, Czuczman MS Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunode-ficient mouse lymphoma model. Clin Cancer Res 2005; 11:5984-92; PMID:16115943; http://dx.doi.org/10.1158/1078-0432.CCR- 05-0577
106. Yu P, Lee Y, Liu W., Chin RK, Wang J, Wang Y, et al Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5:141-9; PMID:14704792; http://dx.doi.org/10.1038/ni1029
107. Moschetta M, Pretto F, Berndt A., Galler K, Richter P, Bassi A., et al Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 2012; 72:1814-24; PMID:22392081; http://dx.doi.org/10.1158/0008-5472.CAN-11-1919
108. Curnis F, Sacchi A, Borgna L., Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18:1185-90; PMID:11062439; http://dx.doi.org/10.1038/81183
109. Curnis F, Sacchi A, Corti A. Improving chemothera-peutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110:475-82; PMID:12189241
110. Calcinotto A, Grioni M, Jachetti E., Curnis F, Mondino A, Parmiani G., et al Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012; 188:2687-94; PMID:22323546; http://dx.doi.org/10.4049/jimmunol. 1101877
111. Bellone M, Calcinotto A, Corti A. Won't you come on in? How to favor lymphocyte infiltration in tumors. OncoImmunology 2012; 1:98-9; http://dx.doi.org/10.4161/onci.20213
112. Johansson A, Hamzah J, Payne C.J., Ganss R. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A 2012; 109:7841-6; PMID:22547817; http://dx.doi.org/10.1073/pnas.1118296109
113. Fiedler U, Reiss Y, Scharpfenecker M., Grunow V, Koidl S, Thurston G., et al Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-9; PMID:16462802; http://dx.doi.org/10.1038/nm1351
114. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C., et al Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70:5270-80; PMID:20530679; http://dx.doi.org/10.1158/0008-5472.CAN-10-0012
115. Shrimali RK, Yu Z, Theoret M.R., Chinnasamy D., Restifo N P, Rosenberg SA Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immuno-therapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153
116. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
117. Curran MA, Kim M, Montalvo W., Al-Shamkhani A, Allison J P. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; PMID:21559358; http://dx.doi.org/10.1371/journal.pone.0019499
118. Fisher DT, Chen Q, Skitzki J.J., Muhitch JB, Zhou L, Appenheimer MM, et al IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011; 121:3846-59; PMID:21926464; http://dx.doi.org/10.1172/JCI44952
119. Shinkawa T, Nakamura K, Yamane N., Shoji-Hosaka E, Kanda Y, Sakurada M., et al The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
120. Yamane-Ohnuki N., Kinoshita S, Inoue-Urakubo M, Kusunoki M., Iida S, Nakano R, et al Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87:614-22; PMID:15352059; http://dx.doi.org/10.1002/bit.20151
121. Okazaki A, Shoji-Hosaka E, Nakamura K., Wakitani M, Uchida K, Kakita S., et al Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy
122. Junttila TT, Parsons K, Olsson C., Lu Y, Xin Y, Theriault J., et al Superior in vivo efficacy of afucosylated trastu-zumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70:4481-9; PMID:20484044; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704
123. Ishida T, Joh T, Uike N., Yamamoto K, Utsunomiya A, Yoshida S., et al Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30:837-42; PMID:22312108; http://dx.doi.org/10.1200/JCO.2011.37.3472
124. Umaña P., Jean-Mairet J, Moudry R., Amstutz H, Bailey JE Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176-80; PMID:10052355; http://dx.doi.org/10.1038/6179
125. Hamilton SR, Davidson RC, Sethuraman N, Nett J.H., Jiang Y., Rios S, et al Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006; 313:1441-3; PMID:16960007; http://dx.doi.org/10.1126/science. 1130256
126. Li H, Sethuraman N, Stadheim T.A., Zha D., Prinz B, Ballew N, et al Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24:210-5; PMID:16429149; http://dx.doi.org/10.1038/nbt1178
127. Lazar GA, Dang W, Karki S., Vafa O, Peng JS, Hyun L, et al Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103
128. Desjarlais JR, Lazar GA Modulation of antibody effector function. Exp Cell Res 2011; 317:1278-85; PMID:21459085; http://dx.doi.org/10.1016/j.yexcr. 2011.03.018
129. Hogarth PM, Pietersz GA Fcreceptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012; 11:311-31; PMID:22460124; http://dx.doi.org/10.1038/nrd2909
130. Trédan O., Galmarini CM, Patel K, Tannock IF Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:1441-54; PMID:17895480; http://dx.doi.org/10.1093/jnci/djm135
131. Marcucci F, Corti A. Improving drug penetration to curb tumor drug resistance. Drug Discov Today 2012; 17:1139-46; PMID:22706017; http://dx.doi.org/10.1016/j.drudis.2012.06.004